Clare O'Brien regularly advises major US and international clients on their public and private mergers and acquisition transactions, including public company restructurings, joint ventures and large public transactions. She also provides counsel on corporate law questions, including corporate governance matters.
Ms O'Brien has been consistently acknowledged as a leading M&A lawyer and has received a "Dealmaker of the Year" award by The American Lawyer.
Her recent significant representations include:
- Representation of Raytheon Company in its pending merger of equals transaction with United Technologies Corporation;
- Ardagh Group in various transactions, including its acquisition of certain metal beverage can manufacturing assets from Ball Corporation and Rexam PLC with an enterprise value of $3.42 billion, and its sale of Anchor Glass Container Corporation to an affiliate of KPS Capital Partners LP;
- Boston Scientific Corporation in various transactions, including its pending acquisition of BTG plc, a public company organized under the laws of England and Wales, its acquisition of the advanced biologic tissue capabilities of Neovasc Inc. and 15% of Neovasc's common shares, its acquisition of the men's health and prostate health businesses of Endo International plc, the sale of its neurovascular business to Stryker Corporation, its acquisition of and the restructuring of its interests in Advanced Bionics Corporation, its acquisition of Guidant Corporation, the sale of Guidant's vascular businesses to Abbott Laboratories and in various corporate and other transactional matters;
- HeartWare International, Inc. in its sale to Medtronic, Inc., and its terminated acquisition transaction with Thoratec Corporation